New drugs in recurrent high grade gliomas.
AA Brandes, LM Pasetto, S Monfardini - Anticancer research, 2000 - europepmc.org
AA Brandes, LM Pasetto, S Monfardini
Anticancer research, 2000•europepmc.orgBackground The incidence of Central Nervous System (CNS) neoplasias ranges from 3.8 to
5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is
problematic; chemotherapy is experimental, primarily because the response is palliative and
of limited duration. Materials and methods This article analyzes the new drugs that have
been introduced for the treatment of these patients in recent years, the objective response,
the TTP and the MST. Results The most encouraging results to date come from studies of …
5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is
problematic; chemotherapy is experimental, primarily because the response is palliative and
of limited duration. Materials and methods This article analyzes the new drugs that have
been introduced for the treatment of these patients in recent years, the objective response,
the TTP and the MST. Results The most encouraging results to date come from studies of …
Background
The incidence of Central Nervous System (CNS) neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration.
Materials and methods
This article analyzes the new drugs that have been introduced for the treatment of these patients in recent years, the objective response, the TTP and the MST.
Results
The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years.
Conclusion
New approaches to chemotherapy treatment are necessary. Enrollment of patients into rigorous, well-conducted, clinical trials, both at tumor diagnosis and after tumor recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.
europepmc.org